Compounds > n-succinimidyl-4-fluorobenzoate

n-succinimidyl-4-fluorobenzoate and Liver-Neoplasms

n-succinimidyl-4-fluorobenzoate has been researched along with Liver-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for n-succinimidyl-4-fluorobenzoate and Liver-Neoplasms

Article	Year
Fluorine-18 radiolabeling of low-density lipoproteins: a potential approach for characterization and differentiation of metabolism of native and oxidized low-density lipoproteins in vivo. Nuclear medicine and biology, 2004, Volume: 31, Issue:8 Oxidative modification of low-density lipoprotein (LDL) is regarded as a crucial event in atherogenesis. Assessing the metabolic fate of oxidized LDL (oxLDL) in vivo with radiotracer techniques is hindered by the lack of suitable sensitive and specific radiolabeling methods. We evaluated an improved methodology based on the radiolabeling of native LDL (nLDL) and oxLDL with the positron emitter fluorine-18 ((18)F) by conjugation with N-succinimidyl-4-[(18)F]fluorobenzoate ([(18)F]SFB). We investigated whether radiolabeling of LDL induces adverse structural modifications. Results suggest that radiolabeling of both nLDL and oxLDL using [(18)F]SFB causes neither additional oxidative structural modifications of LDL lipids and proteins nor alteration of their biological activity and functionality, respectively. Thus, radiolabeling of LDL using [(18)F]SFB could prove to be a promising approach for studying the kinetics of oxLDL in vivo. Topics: Benzoates; Carcinoma, Hepatocellular; Cell Line; Feasibility Studies; Humans; Lipoproteins, LDL; Liver Neoplasms; Metabolic Clearance Rate; Monocytes; Positron-Emission Tomography; Radiopharmaceuticals; Succinimides	2004

Article

Year

Fluorine-18 radiolabeling of low-density lipoproteins: a potential approach for characterization and differentiation of metabolism of native and oxidized low-density lipoproteins in vivo.

Nuclear medicine and biology, 2004, Volume: 31, Issue:8

Oxidative modification of low-density lipoprotein (LDL) is regarded as a crucial event in atherogenesis. Assessing the metabolic fate of oxidized LDL (oxLDL) in vivo with radiotracer techniques is hindered by the lack of suitable sensitive and specific radiolabeling methods. We evaluated an improved methodology based on the radiolabeling of native LDL (nLDL) and oxLDL with the positron emitter fluorine-18 ((18)F) by conjugation with N-succinimidyl-4-[(18)F]fluorobenzoate ([(18)F]SFB). We investigated whether radiolabeling of LDL induces adverse structural modifications. Results suggest that radiolabeling of both nLDL and oxLDL using [(18)F]SFB causes neither additional oxidative structural modifications of LDL lipids and proteins nor alteration of their biological activity and functionality, respectively. Thus, radiolabeling of LDL using [(18)F]SFB could prove to be a promising approach for studying the kinetics of oxLDL in vivo.

Topics: Benzoates; Carcinoma, Hepatocellular; Cell Line; Feasibility Studies; Humans; Lipoproteins, LDL; Liver Neoplasms; Metabolic Clearance Rate; Monocytes; Positron-Emission Tomography; Radiopharmaceuticals; Succinimides

2004